Systematic review of independent pharmacist prescribing for the treatment of cardiometabolic factors in chronic non-communicable diseases

Given that hypertension is one of the major risk factors for morbidity and mortality, expansion of care for this condition to include IPPs embedded in both hospital and community settings has marked potential for public health benefit. Although available evidence supports the feasibility of IPP for glycaemic control, more adequate evaluations are needed to determine safety and efficacy. Finally, IPP for hypercholesterolaemia likely requires additional investigation, including studies specifically targeting change in cholesterol.